Canadian Healthcare Stocks Under Review: Valeant Pharma International, Knight Therapeutics, Merus Labs International, and Nuvo Pharma

LONDON, UK / ACCESSWIRE / June 30, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Drug Manufacturers industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Valeant Pharmaceuticals International, Knight Therapeutics, Merus Labs International, and Nuvo Pharmaceuticals. Register for these free reports at: http://protraderdaily.com/register/.

On Thursday, June 29, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,213.42, 0.93% lower, with a total volume of 342,617,533 shares.

Additionally, the Healthcare index was slightly down by 0.96%, ending the session at 71.00.

Pro-Trader Daily’s complimentary research reports on the following stocks are now available: Valeant Pharmaceuticals International Inc. (TSX: VRX), Knight Therapeutics Inc. (TSX: GUD), Merus Labs International Inc. (TSX: MSL), and Nuvo Pharmaceuticals Inc. (TSX: NRI). Sign up now for your free membership and research reports at: http://protraderdaily.com/register/.

Valeant Pharmaceuticals International Inc. (TSX: VRX)

Laval, Canada headquartered Valeant Pharmaceuticals International Inc.’s stock edged 0.22% higher, to finish Thursday’s session at $22.46 with a total volume of 3.72 million shares traded. Over the last one month and the previous three months, Valeant Pharma’s shares have surged 36.29% and 52.27%, respectively. Shares of the Company, which operates as a pharmaceutical and medical device company worldwide, are trading above its 50-day and 200-day moving averages. Valeant Pharma’s 50-day moving average of $18.03 is above its 200-day moving average of $17.27. See our research report on VRX.TO at: http://protraderdaily.com/optin/?symbol=VRX.

Knight Therapeutics Inc. (TSX: GUD)

On Thursday, shares in Montreal, Canada headquartered Knight Therapeutics Inc. recorded a trading volume of 420,094 shares, which was higher than their three months average volume of 120,382 shares. The stock ended the day 0.58% lower at $10.29. Knight Therapeutics’ stock has gained 3.31% in the last one month and 24.43% in the previous one year. The Company’s shares are trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $10.28 is above its 50-day moving average of $10.01. Shares of the Company, which engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally, are trading at a PE ratio of 57.81. The complimentary research report on GUD.TO at: http://protraderdaily.com/optin/?symbol=GUD.

Merus Labs International Inc. (TSX: MSL)

On Thursday, shares in Toronto, Canada headquartered Merus Labs International Inc. ended the session flat at $1.63 with a total volume of 1.21 million shares traded. Merus Labs’ shares have gained 1.87% in the last one month and 32.52% in the previous three months. Shares of the Company, which owns, markets, and distributes pharmaceutical products primarily in Europe and Canada, are trading above its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $1.60 is greater than its 200-day moving average of $1.25. Register for free and access the latest research report on MSL.TO at: http://protraderdaily.com/optin/?symbol=MSL.

Nuvo Pharmaceuticals Inc. (TSX: NRI)

Mississauga, Canada headquartered Nuvo Pharmaceuticals Inc.’s stock closed the day 1.17% higher at $4.32. The stock recorded a trading volume of 100 shares, below its three months average volume of 29,706 shares. The Company’s shares are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $5.22 is greater than its 50-day moving average of $4.43. Shares of Nuvo Pharma, which produces and sells pharmaceutical products in the US, Canada, and Europe, are trading at a PE ratio of 6.48. Get free access to your research report on NRI.TO at: http://protraderdaily.com/optin/?symbol=NRI.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467209